Taiwan-based Formosa Pharmaceuticals (TPE: 6838) announced a licensing agreement with India-headquartered Cipla Limited (BOM: 500087, NSE: CIPLA). Formosa is granting Cipla commercialization rights for its APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) in 11 countries, including India, Nepal, Sri Lanka, Bangladesh, Malaysia, Myanmar, Kenya, Nigeria, South Africa, Argentina, and Colombia.
Deal Details
Under the terms of the agreement, Formosa will transfer commercialization rights for APP13007 to Cipla across the specified countries. The deal specifics, including financial terms, have not been disclosed.
Product Profile
APP13007 is a corticosteroid-based ophthalmic nanosuspension developed by Formosa Pharmaceuticals. The active ingredient, clobetasol propionate, is formulated using Formosa’s proprietary APNT nanoparticle technology, allowing for a dosing regimen of twice daily for 14 days. This product is protected by patents and has received approval from the US Food and Drug Administration (USFDA).-Fineline Info & Tech
Leave a Reply